KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $0.0.

  • GoodRx Holdings' EPS (Basic) fell 6898.09% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.08, marking a year-over-year increase of 36666.67%. This contributed to the annual value of $0.04 for FY2024, which is 31245.05% up from last year.
  • As of Q3 2025, GoodRx Holdings' EPS (Basic) stood at $0.0, which was down 6898.09% from $0.04 recorded in Q2 2025.
  • GoodRx Holdings' 5-year EPS (Basic) high stood at $0.14 for Q2 2023, and its period low was -$0.1 during Q4 2021.
  • Moreover, its 5-year median value for EPS (Basic) was $0.0 (2024), whereas its average is -$0.0.
  • Data for GoodRx Holdings' EPS (Basic) shows a peak YoY increase of 419022.61% (in 2023) and a maximum YoY decrease of 50000.0% (in 2023) over the last 5 years.
  • Over the past 5 years, GoodRx Holdings' EPS (Basic) (Quarter) stood at -$0.1 in 2021, then soared by 90.0% to -$0.01 in 2022, then plummeted by 500.0% to -$0.06 in 2023, then skyrocketed by 129.12% to $0.02 in 2024, then crashed by 82.25% to $0.0 in 2025.
  • Its EPS (Basic) stands at $0.0 for Q3 2025, versus $0.04 for Q2 2025 and $0.03 for Q1 2025.